C/EBPβ+/+ mice with severe liver fibrosis induced by an 8-week CCl4 treatment, while continuing on CCl4, were treated with the cell permeant RSK-inhibitory peptide for 4 or 8 weeks. The gene discussed is CEBPB; the disease is Hepatic fibrosis.